We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Combining Gold Nanoparticles with Viruses

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Combining Gold Nanoparticles with Viruses"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
Source: Nanowerk LLC

Gold nanoparticles have shown promise for cancer therapy by virtue of their ability to absorb laser light, heat up and thus kill the tumor.

However, in order for the gold nanoparticles to have their therapeutic effect they need to be taken up specifically by tumor cells.

Researchers have now used targeted viral vectors as carriers to bring the gold nanoparticles to the location where they need to work.

This opens up the possibility of combining two types of treatment: heating the tumor using the gold nanoparticles, and killing the tumor using gene therapy.

An international group of researchers led by scientists from the Gene Therapy Center at the University of Alabama (UAB) recently published findings that indicate the possibility of using adenoviral vectors as carriers for gold nanoparticles.

Their paper, titled "Covalently Linked Au Nanoparticles to a Viral Vector: Potential for Combined Photothermal and Gene Cancer Therapy" was published on March 15, 2006 in the online edition of Nano Letters.

Dr. Maaike Everts from UAB, first author of the paper, explained their findings to Nanowerk, "We found that coupling gold nanoparticles to the surface of viruses that are targeted to tumor cells allows them to ‘hitchhike’ along with the virus to the tumor, without impeding the ability of the virus to infect and target tumor cells."

Dr. David T. Curiel, who heads the Gene Therapy Center, and his team are developing cancer gene therapy approaches by using viruses, in particular adenovirus.

Adenovirus causes the common cold, but the particular viruses Curiel and his group use have been genetically altered in order to stop them from multiplying, thus rendering them harmless to the human body.

"We are able to target these viruses - also known as ‘viral vectors’ in a gene therapy context - to tumors by virtue of specific markers that are expressed on cancer cells, which can be recognized by our viruses," Curiel says.

Previously, the payload of a viral vector was either a corrective gene (an example is a correct copy of the p53 gene, which is mutated in a lot of cancers) or a gene that encodes a toxic product that is able to kill the tumor cell.

"The novelty in our work," says Everts "is the use of metal nanoparticles as a payload of targeted viral vectors."

"Since the viruses are still able to deliver a gene of interest, even with the gold nanoparticles coupled to their surface, a combination of both payloads is a possibility, which may work better than either alone."

"We are working on strategies to incorporate modalities 2) and 4) as well, but there is still a lot of work that needs to be done before that can be accomplished," Everts says.